BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 23 filers reported holding BAXTER INTL INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $303,090 | -8.8% | 8,031 | -2.0% | 0.02% | -5.6% |
Q1 2023 | $332,227 | -21.4% | 8,191 | -1.2% | 0.02% | -25.0% |
Q4 2022 | $422,592 | -5.5% | 8,291 | 0.0% | 0.02% | -14.3% |
Q3 2022 | $447,000 | -16.6% | 8,291 | -0.7% | 0.03% | -9.7% |
Q2 2022 | $536,000 | +4.5% | 8,351 | +26.2% | 0.03% | +14.8% |
Q1 2022 | $513,000 | -9.7% | 6,616 | 0.0% | 0.03% | -6.9% |
Q4 2021 | $568,000 | +3.5% | 6,616 | -2.9% | 0.03% | -9.4% |
Q2 2021 | $549,000 | +42.6% | 6,816 | +49.3% | 0.03% | +33.3% |
Q1 2021 | $385,000 | -20.5% | 4,565 | -24.3% | 0.02% | -27.3% |
Q4 2020 | $484,000 | -0.2% | 6,031 | 0.0% | 0.03% | -15.4% |
Q3 2020 | $485,000 | -21.0% | 6,031 | -15.4% | 0.04% | -26.4% |
Q2 2020 | $614,000 | -16.8% | 7,131 | -21.5% | 0.05% | -19.7% |
Q1 2020 | $738,000 | -3.5% | 9,086 | -0.6% | 0.07% | +29.4% |
Q4 2019 | $765,000 | +22.6% | 9,144 | +28.2% | 0.05% | +4.1% |
Q3 2019 | $624,000 | +35.1% | 7,131 | +26.4% | 0.05% | +36.1% |
Q2 2019 | $462,000 | +36.3% | 5,643 | +35.5% | 0.04% | +28.6% |
Q1 2019 | $339,000 | +23.7% | 4,165 | 0.0% | 0.03% | +7.7% |
Q4 2018 | $274,000 | +3.8% | 4,165 | +21.7% | 0.03% | +23.8% |
Q3 2018 | $264,000 | +4.8% | 3,422 | -12.3% | 0.02% | +5.0% |
Q4 2017 | $252,000 | +1.6% | 3,900 | -1.5% | 0.02% | +5.3% |
Q3 2017 | $248,000 | +3.3% | 3,960 | 0.0% | 0.02% | 0.0% |
Q2 2017 | $240,000 | +13.7% | 3,960 | -2.5% | 0.02% | +11.8% |
Q1 2017 | $211,000 | – | 4,060 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Tavio Capital LLC | 68,405 | $5,890,000 | 7.81% |
Iron Triangle Partners LP | 330,000 | $28,413,000 | 7.16% |
Veritas Asset Management LLP | 8,942,428 | $769,943,000 | 5.64% |
TSFG, LLC | 93,405 | $8,042,000 | 5.31% |
GENERATION INVESTMENT MANAGEMENT LLP | 10,606,094 | $913,185,000 | 5.27% |
Third Point | 4,000,000 | $344,400,000 | 4.72% |
Avidity Partners Management LP | 800,900 | $68,957,000 | 4.42% |
Palmer Knight Co | 62,275 | $5,362,000 | 4.17% |
Eos Focused Equity Management, L.P. | 36,786 | $3,167,000 | 3.70% |
Dundas Partners LLP | 196,133 | $16,887,000 | 3.69% |